Viking Therapeutics, Inc. APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition
Viking Therapeutics, Inc. (VKTX) reported APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition of $11.13 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition · last filed 2026-07-29
- Viking Therapeutics, Inc. apic, share-based payment arrangement, espp, increase for cost recognition for the quarter ending 2026-06-30 was $11.13M, a 17.82% decline year-over-year.
- Viking Therapeutics, Inc. apic, share-based payment arrangement, espp, increase for cost recognition for the quarter ending 2026-03-31 was $10.34M, a 8.91% decline year-over-year.
- Viking Therapeutics, Inc. apic, share-based payment arrangement, espp, increase for cost recognition for the quarter ending 2025-12-31 was $8.59M, a 51.53% increase year-over-year.
- Viking Therapeutics, Inc. apic, share-based payment arrangement, espp, increase for cost recognition for the quarter ending 2025-09-30 was $7.34M, a 18.33% decline year-over-year.
- Viking Therapeutics, Inc. apic, share-based payment arrangement, espp, increase for cost recognition for fiscal 2025 was $40.82M, a 37.38% increase from fiscal 2024.
- Viking Therapeutics, Inc. apic, share-based payment arrangement, espp, increase for cost recognition for fiscal 2024 was $29.71M, a 77.39% increase from fiscal 2023.
- Viking Therapeutics, Inc. apic, share-based payment arrangement, espp, increase for cost recognition for fiscal 2023 was $16.75M, a 93.13% increase from fiscal 2022.
- Viking Therapeutics, Inc. apic, share-based payment arrangement, espp, increase for cost recognition for fiscal 2022 was $8.67M, a 42.18% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition 3 month as first filed | APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition 6 month as first filed | APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition 9 month as first filed | APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition 12 month | APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $11.13M 10-Q · filed 2026-07-29 | $21.47M 10-Q · filed 2026-07-29 | $30.06M derived: sum of 3 quarters · filed 2026-07-29 | $37.39M derived: sum of 4 quarters · filed 2026-07-29 | ||||
| 2026-03-31 | $10.34M 10-Q · filed 2026-04-30 | $18.92M derived: sum of 2 quarters · filed 2026-04-30 | $26.26M derived: sum of 3 quarters · filed 2026-04-30 | $39.81M derived: sum of 4 quarters · filed 2026-07-29 | ||||
| 2025-12-31 | $8.59M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $15.92M derived: sum of 2 quarters · filed 2026-02-11 | $29.47M derived: sum of 3 quarters · filed 2026-07-29 | $40.82M 10-K · filed 2026-02-11 | ||||
| 2025-09-30 | $7.34M 10-Q · filed 2025-10-23 | $20.88M derived: sum of 2 quarters · filed 2026-07-29 | $32.23M 10-Q · filed 2025-10-23 | $37.90M derived: sum of 4 quarters · filed 2026-07-29 | ||||
| 2025-06-30 | $13.55M 10-Q · filed 2026-07-29 | $24.89M 10-Q · filed 2026-07-29 | $30.56M derived: sum of 3 quarters · filed 2026-07-29 | $39.54M derived: sum of 4 quarters · filed 2026-07-29 | ||||
| 2025-03-31 | $11.35M 10-Q · filed 2026-04-30 | $17.02M derived: sum of 2 quarters · filed 2026-04-30 | $26.00M derived: sum of 3 quarters · filed 2026-04-30 | $33.08M derived: sum of 4 quarters · filed 2026-04-30 | ||||
| 2024-12-31 | $5.67M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $14.65M derived: sum of 2 quarters · filed 2026-02-11 | $21.73M derived: sum of 3 quarters · filed 2026-02-11 | $29.71M 10-K · filed 2026-02-11 | ||||
| 2024-09-30 | $8.98M 10-Q · filed 2025-10-23 | $16.06M derived: sum of 2 quarters · filed 2025-10-23 | $24.05M 10-Q · filed 2025-10-23 | $28.13M derived: sum of 4 quarters · filed 2026-02-11 | ||||
| 2024-06-30 | $7.08M 10-Q · filed 2025-07-23 | $15.06M 10-Q · filed 2025-07-23 | $19.14M derived: sum of 3 quarters · filed 2026-02-11 | $23.62M derived: sum of 4 quarters · filed 2026-02-11 | ||||
| 2024-03-31 | $7.98M 10-Q · filed 2025-04-24 | $12.06M derived: sum of 2 quarters · filed 2026-02-11 | $16.54M derived: sum of 3 quarters · filed 2026-02-11 | $21.16M derived: sum of 4 quarters · filed 2026-02-11 | ||||
| 2023-12-31 | $4.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $8.56M derived: sum of 2 quarters · filed 2026-02-11 | $13.18M derived: sum of 3 quarters · filed 2026-02-11 | $16.75M 10-K · filed 2026-02-11 | ||||
| 2023-09-30 | $4.48M 10-Q · filed 2024-10-23 | $9.10M derived: sum of 2 quarters · filed 2024-10-23 | $12.67M 10-Q · filed 2024-10-23 | $14.83M derived: sum of 4 quarters · filed 2025-02-26 | ||||
| 2023-06-30 | $4.62M 10-Q · filed 2024-07-24 | $8.19M 10-Q · filed 2024-07-24 | $10.35M derived: sum of 3 quarters · filed 2025-02-26 | $12.29M derived: sum of 4 quarters · filed 2025-02-26 | ||||
| 2023-03-31 | $3.57M 10-Q · filed 2024-04-25 | $5.72M derived: sum of 2 quarters · filed 2025-02-26 | $7.67M derived: sum of 3 quarters · filed 2025-02-26 | $9.88M derived: sum of 4 quarters · filed 2025-02-26 | ||||
| 2022-12-31 | $2.16M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $4.10M derived: sum of 2 quarters · filed 2025-02-26 | $6.32M derived: sum of 3 quarters · filed 2025-02-26 | $8.67M 10-K · filed 2025-02-26 | ||||
| 2022-09-30 | $1.94M 10-Q · filed 2023-10-25 | $4.16M derived: sum of 2 quarters · filed 2023-10-25 | $6.52M 10-Q · filed 2023-10-25 | $7.95M derived: sum of 4 quarters · filed 2024-02-07 | ||||
| 2022-06-30 | $2.22M 10-Q · filed 2023-07-26 | $4.58M 10-Q · filed 2023-07-26 | $6.01M derived: sum of 3 quarters · filed 2024-02-07 | $7.61M derived: sum of 4 quarters · filed 2024-02-07 | ||||
| 2022-03-31 | $2.36M 10-Q · filed 2023-04-26 | $3.79M derived: sum of 2 quarters · filed 2024-02-07 | $5.39M derived: sum of 3 quarters · filed 2024-02-07 | $6.88M derived: sum of 4 quarters · filed 2024-02-07 | ||||
| 2021-12-31 | $1.43M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-07 | $3.03M derived: sum of 2 quarters · filed 2024-02-07 | $4.52M derived: sum of 3 quarters · filed 2024-02-07 | $6.10M 10-K · filed 2024-02-07 | ||||
| 2021-09-30 | $1.60M 10-Q · filed 2022-10-26 | $3.09M derived: sum of 2 quarters · filed 2022-10-26 | $4.67M 10-Q · filed 2022-10-26 | $5.71M derived: sum of 4 quarters · filed 2022-10-26 | ||||
| 2021-06-30 | $1.49M 10-Q · filed 2022-07-27 | $3.07M 10-Q · filed 2022-07-27 | $4.11M derived: sum of 3 quarters · filed 2022-07-27 | $5.58M derived: sum of 4 quarters · filed 2022-07-27 | ||||
| 2021-03-31 | $1.58M 10-Q · filed 2022-04-27 | $2.62M derived: sum of 2 quarters · filed 2022-04-27 | $4.09M derived: sum of 3 quarters · filed 2022-04-27 | $5.74M derived: sum of 4 quarters · filed 2022-04-27 | ||||
| 2020-12-31 | $1.04M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-09 | $2.52M derived: sum of 2 quarters · filed 2022-02-09 | $4.17M derived: sum of 3 quarters · filed 2022-02-09 | $5.82M 10-K · filed 2022-02-09 | $5.52M 10-K · filed 2021-02-17 | |||
| 2020-09-30 | $1.48M 10-Q · filed 2021-11-03 | $1.31M 10-Q · filed 2020-10-28 | $3.12M derived: sum of 2 quarters · filed 2021-11-03 | $4.78M 10-Q · filed 2021-11-03 | $4.48M 10-Q · filed 2020-10-28 | $5.72M derived: sum of 4 quarters · filed 2021-11-03 | ||
| 2020-06-30 | $1.65M 10-Q · filed 2021-07-28 | $3.30M 10-Q · filed 2021-07-28 | $3.17M 10-Q · filed 2020-07-29 | $4.25M derived: sum of 3 quarters · filed 2021-07-28 | $5.06M derived: sum of 4 quarters · filed 2021-07-28 | |||
| 2020-03-31 | $1.65M 10-Q · filed 2021-04-28 | $1.52M 10-Q · filed 2020-04-30 | $2.60M derived: sum of 2 quarters · filed 2021-04-28 | $3.41M derived: sum of 3 quarters · filed 2021-04-28 | $4.29M derived: sum of 4 quarters · filed 2021-04-28 | |||
| 2019-12-31 | $949.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-17 | $1.76M derived: sum of 2 quarters · filed 2021-02-17 | $2.64M derived: sum of 3 quarters · filed 2021-02-17 | $3.59M 10-K · filed 2021-02-17 | ||||
| 2019-09-30 | $810.00K 10-Q · filed 2020-10-28 | $1.69M derived: sum of 2 quarters · filed 2020-10-28 | $2.64M 10-Q · filed 2020-10-28 | $3.23M derived: sum of 4 quarters · filed 2020-10-28 | ||||
| 2019-06-30 | $884.00K 10-Q · filed 2020-07-29 | $1.83M 10-Q · filed 2020-07-29 | $2.42M derived: sum of 3 quarters · filed 2020-07-29 | $3.17M derived: sum of 4 quarters · filed 2020-07-29 | ||||
| 2019-03-31 | $949.00K 10-Q · filed 2020-04-30 | $1.54M derived: sum of 2 quarters · filed 2020-04-30 | $2.29M derived: sum of 3 quarters · filed 2020-04-30 | $2.82M derived: sum of 4 quarters · filed 2020-04-30 | ||||
| 2018-12-31 | $591.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26 | $1.34M derived: sum of 2 quarters · filed 2020-02-26 | $1.87M derived: sum of 3 quarters · filed 2020-02-26 | $2.48M 10-K · filed 2020-02-26 | ||||
| 2018-09-30 | $747.00K 10-Q · filed 2019-11-05 | $1.28M derived: sum of 2 quarters · filed 2019-11-05 | $1.89M 10-Q · filed 2019-11-05 | $2.24M derived: sum of 4 quarters · filed 2019-11-05 | ||||
| 2018-06-30 | $531.00K 10-Q · filed 2019-08-01 | $1.14M 10-Q · filed 2019-08-01 | $1.50M derived: sum of 3 quarters · filed 2019-08-01 | $1.84M derived: sum of 4 quarters · filed 2019-08-01 | ||||
| 2018-03-31 | $610.00K 10-Q · filed 2019-05-02 | $966.00K derived: sum of 2 quarters · filed 2019-05-02 | $1.31M derived: sum of 3 quarters · filed 2019-05-02 | |||||
| 2017-12-31 | $356.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-13 | $700.00K derived: sum of 2 quarters · filed 2019-03-13 | $1.43M 10-K · filed 2019-03-13 | $1.43M 10-K · filed 2018-03-07 | ||||
| 2017-09-30 | $344.00K 10-Q · filed 2018-11-07 | $1.07M 10-Q · filed 2018-11-07 | ||||||
| 2016-12-31 | $1.79M 10-K · filed 2018-03-07 | |||||||
| 2015-12-31 | $2.21M 10-K · filed 2017-03-21 | |||||||
| 2014-12-31 | $3.76K 10-K · filed 2016-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |